Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 9, 2005, Pages 943-950

  Aldulaimi, David M ^a   Cox, Mark ^a   Nwokolo, Chuka U ^a   Loft, Duncan E ^a  

^a WALSGRAVE HOSPITAL   (United Kingdom)

Author keywords

Barrett's oesophagus; Oesophageal neoplasms; Screening; Surveillance; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER SURVIVAL; COHORT ANALYSIS; COST OF ILLNESS; ESOPHAGOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ENGLAND; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23944470655     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200509000-00010     Document Type: Article

References (68)

1. Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92:118-124.
2. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99:918-922.
3. Lambert R. An overview of the management of cancer of the esophagus. Gastrointest Endosc Clin N Am 1998; 8:415-434.
4. Lund O, Hasenkam JM, Aagaard MT, Kimose HH. Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia. Br J Surg 1989; 76:1301-1307.
5. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270:1320.
6. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-2053.
7. Aldulaimi D, Jankowski J. Barrett's esophagus: an overview of the molecular biology. Dis Esophagus 1999; 12:177-180.
8. Shaheen NJ, Crosby MA, Bozymski EM, Sandier RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333-338.
9. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43:216-222.
10. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br Med J 2000; 321:1252-1255.
11. Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001; 13:639-645.
12. Lambert R. Barrett's oesophagus: better left alone? Eur J Gastroenterol Hepatol 2001; 13:627-630.
13. Bani-Hani K, Sue-Ling H, Johnston D, Axon AT, Martin IG. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol 2000; 12:649-654.
14. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12:893-897.
15. Fitzgerald RC, Saeed IT, Khoo D, Farthing MJ, Burnham WR. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001; 46:1892-1898.
16. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33:1155-1158.
17. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75:760-763.
18. Wright TA, Gray MR, Morris Al, Gilmore IT, Ellis A, Smart HL, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39:574-579.
19. Watson RGP, Sloan JM. Incidence of adenocarcinoma in Barrett's oesophagus and evaluation of endoscopic surveillance. Eur J Gastroenterol 1991; 3:159-162.
20. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123:461-467.
21. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
22. Nilsson J, Skobe V, Johansson J, Willen R, Johnsson F. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol 2000; 35:10-16.
23. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94:2037-2042.
24. Jankowski JA, Provencale D, Moayeddi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology 2002; 122:588-590.
25. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol 2002; 97:1319-1327.
26. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122:633-640.
27. Shaheen N. Is there a "Barrett's iceberg"? Gastroenterology 2002; 123:636-639.
28. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-1895.
29. Boyer J, Robaszkiewicz M. Guidelines of the French Society of Digestive Endoscopy: monitoring of Barrett's esophagus. The Council of the French Society of Digestive Endoscopy. Endoscopy 2000; 32:498-499.
30. Stein HJ. Oesophageal cancer: screening and surveillance. Results of a concensus conference held at the 6th world conference of the International Society for the Study of Diseases of the Oesophagus. Diseases of the Oesophagus 1996:53-119.
31. Gross CP, Canto Ml, Hixson J, Powe NR. Management of Barrett's esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol 1999; 94:3440-3447.
32. van Sandick JW, Baak JP, van Lanschot JJ, Polkowski W, ten Kate FJ, Obertop H, Offerhaus GJ. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol 2000; 190:177-183.
33. Smith AM, Maxwell-Armstrong CA, Welch NT, Scholefield JH. Surveillance for Barrett's oesophagus in the UK. Br J Surg 1999; 86:276-280.
34. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993; 88:1832-1836.
35. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996; 224:66-71.
36. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95:3383-3387.
37. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120:1630-1639.
38. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nature Genet 1999; 22:106-109.
39. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32:1441-1446.
40. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120:1607-1619.
41. Ferraris R, Bonelli L, Conio M, Fracchia M, Lapertosa G, Aste H. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol 1997; 9:881-885.
42. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116:277-285.
43. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, Reid BJ. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132:612-620.
44. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117:218-228.
45. Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000; 46:9-13.
46. Eloubeidi MA, Homan RK, Martz MD, Theobald KE, Provenzale D. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting. Am J Gastroenterol 1999; 94:2033-2036.
47. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89:670-680.
48. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053.
49. Morales TG, Sampliner RE. Barrett's esophagus: update on screening, surveillance, and treatment. Arch Intern Med 1999; 159:1411-1416.
50. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96:1249-1256.
51. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102:1212-1219.
52. Levine DS, Irvine S, Reid BJ. Natural history of high grade dysplasia in Barrett's oesophagus. Gastroenterology 1996; 110:A:550.
53. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105:40-50.
54. Falk GW, Chittajallu R, Goldblum JR, Biscotti CV, Geisinger KR, Petras RE, et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997; 112:1787-1797.
55. Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg 1996; 223:585-589; discussion 589-591.
56. Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, Peters JH, Kiyabu M. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230:433-438; discussion 438-440.
57. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:1028-1032.
58. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105:383-387; discussion 387-388.
59. Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108:813-821; discussion 821-812.
60. Rusch VW, Levine DS, Haggitt R, Reid BJ. The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer 1994; 74:1225-1229.
61. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93:536-541.
62. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH, Banerjee SK. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol 1996; 91:981-986.
63. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39:5-8.
64. Sampliner REMC, Fennerty MB, Garewal HS. Prospective incidence of cancer in Barrett's oesophagus. Gastroenterology 1991; 100:A153.
65. Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, Watkins E Jr. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151:2212-2216.
66. Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989; 34:1336-1339.
67. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989; 30:14-18.
68. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313:857-859.